Roxadustat Shows Promise in Combating Obesity-Related Metabolic and Skeletal Issues

CHENGDU, SICHUAN, CHINA – March 17, 2026 – Obesity not only increases the risk of diabetes and cardiovascular disease but also negatively impacts bone strength and repair. Researchers have found that activating hypoxia-inducible factor (HIF) signaling with the drug Roxadustat may offer a therapeutic strategy to address both metabolic and skeletal deterioration in obesity.

The Link Between Obesity, Metabolism, and Bone Health

Excess body fat can disrupt bone metabolism, weaken bone quality, and impair fracture repair. In individuals with metabolic disorders, bone marrow can accumulate fat, interfering with bone-forming cells and damaging the vascular networks essential for skeletal tissue support. These changes elevate fracture risk and hinder the body’s ability to regenerate bone after injury. Despite these clinical challenges, the underlying biological mechanisms connecting metabolic disease and bone health have remained unclear.

HIF Activation and Roxadustat: A Potential Solution

A research team led by Professor Christa Maes from KU Leuven in Belgium investigated the role of HIF signaling, a molecular pathway that helps cells adapt to low-oxygen environments while regulating metabolism, blood vessel formation, and tissue repair. Using a mouse model of high-fat diet (HFD)-induced obesity, the team administered Roxadustat, a HIF-prolyl-hydroxylase-domain enzyme (PHD) inhibitor already approved for treating certain forms of anemia Bone Research.

Key Findings from the Study

The experiments revealed significant metabolic benefits in the treated mice. Activation of the hypoxia signaling pathway reduced body-weight gain and limited peripheral fat accumulation, even with continued exposure to a high-fat diet. The treated mice also exhibited improved glucose tolerance, indicating better blood sugar control. These improvements were associated with increased energy expenditure, suggesting the intervention helped the body burn more energy.

Importantly, Roxadustat also had protective effects on bone tissue. The treatment prevented the abnormal buildup of fat in bone marrow and preserved the vascular network within the bone, which is crucial for supplying oxygen, nutrients, and signals that support bone maintenance and regeneration.

mice treated with Roxadustat displayed improved fracture healing compared to untreated obese animals, demonstrating that activation of hypoxia signaling can restore the bone’s regenerative potential PubMed.

Implications and Future Research

“Our findings reveal that activation of hypoxia signaling using PHD inhibitors has dual beneficial effects, simultaneously improving metabolism and bone health,” says Prof. Maes.

The research highlights the potential ripple effects across multiple fields, including diabetes, aging, and regenerative medicine. Therapies activating hypoxia signaling could potentially reduce bone complications in individuals with obesity or prediabetes. Future therapies may reduce fracture risk, improve recovery after bone injuries, and address metabolic dysfunction in an integrated strategy.

About KU Leuven

KU Leuven is a leading research university in Europe, renowned for its excellence in science, medicine, and engineering. Founded in 1425, the university combines academic tradition with innovation and global collaboration KU Leuven.

Funding Information

This research was supported by grants from the Research Foundation Flanders (FWO) to Christa Maes. Additional funding was provided through postdoctoral and PhD fellowships Bone Research.